406 related articles for article (PubMed ID: 26499920)
21. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
Jaffe GJ; Pavesio CE;
Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
[TBL] [Abstract][Full Text] [Related]
22. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
Jaffe GJ
Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
[TBL] [Abstract][Full Text] [Related]
23. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.
; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Sugar EA
Am J Ophthalmol; 2010 Apr; 149(4):550-561.e10. PubMed ID: 20097325
[TBL] [Abstract][Full Text] [Related]
24. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis.
Oh EK; Lee EK; Yu HG
Can J Ophthalmol; 2014 Jun; 49(3):273-8. PubMed ID: 24862774
[TBL] [Abstract][Full Text] [Related]
28. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.
Friedman DS; Holbrook JT; Ansari H; Alexander J; Burke A; Reed SB; Katz J; Thorne JE; Lightman SL; Kempen JH;
Ophthalmology; 2013 Aug; 120(8):1571-9. PubMed ID: 23601801
[TBL] [Abstract][Full Text] [Related]
29. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
30. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
[TBL] [Abstract][Full Text] [Related]
31. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
Jaffe GJ; Foster CS; Pavesio CE; Paggiarino DA; Riedel GE
Ophthalmology; 2019 Apr; 126(4):601-610. PubMed ID: 30367884
[TBL] [Abstract][Full Text] [Related]
32. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.
Buhl L; Thurau S; Kern C
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176
[TBL] [Abstract][Full Text] [Related]
33. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
[TBL] [Abstract][Full Text] [Related]
34. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.
Bollinger K; Kim J; Lowder CY; Kaiser PK; Smith SD
Ophthalmology; 2011 Oct; 118(10):1927-31. PubMed ID: 21652079
[TBL] [Abstract][Full Text] [Related]
35. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
36. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
Lowder C; Belfort R; Lightman S; Foster CS; Robinson MR; Schiffman RM; Li XY; Cui H; Whitcup SM;
Arch Ophthalmol; 2011 May; 129(5):545-53. PubMed ID: 21220619
[TBL] [Abstract][Full Text] [Related]
37. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
38. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.
Zarranz-Ventura J; Carreño E; Johnston RL; Mohammed Q; Ross AH; Barker C; Fonollosa A; Artaraz J; Pelegrin L; Adan A; Lee RW; Dick AD; Sallam A
Am J Ophthalmol; 2014 Dec; 158(6):1136-1145.e5. PubMed ID: 25217856
[TBL] [Abstract][Full Text] [Related]
39. Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes.
Jabs DA; Sugar EA; Burke AE; Altaweel MM; Dunn JP; Gangaputra S; Kempen JH; Pepple KL; Stawell RJ; Holbrook JT;
Am J Ophthalmol; 2023 Oct; 254():210-220. PubMed ID: 37406846
[TBL] [Abstract][Full Text] [Related]
40. Long-term visual acuity and its predictors after cataract surgery in patients with uveitis.
Yoeruek E; Deuter C; Gieselmann S; Saygili O; Spitzer MS; Tatar O; Bartz-Schmidt KU; Szurman P
Eur J Ophthalmol; 2010; 20(4):694-701. PubMed ID: 20213617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
